Updated data showed the biotech's approach to the rare lung and liver condition helped restore functional protective proteins ...
Investors had reservations over data from Maze for a drug that could compete with a candidate from Vertex in a ...
Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two ...
If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results